In summary, IL-17 acts as a promoter of cardiac fibrosis in multifactorial heart failure, including sympathetic overactivation and ischemic heart failure, suggesting it as a significant therapeutic target for heart failure treatment. The gene discussed is IL17A; the disease is fibrosis.